MedDataX Logo

Italian Prospective Data Collection for Better Patient Characterization in a Highly Treatment Experienced Population

NCT ID: NCT00614302

Last Updated: 2009-10-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

428 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Data collection for better patient characterization in a highly treatment experienced population. Studying the clinical practice for the treatment of HIV multiexperienced patients in the real life.

The research will be divided into two phases:

* The first phase intends to define and understand the clinical practice using a questionnaire about general topics: definitions of multiexperienced patients and VL failure, therapeutic strategies and behaviour in particular cases.
* The second part of the research will collect the clinical data of double PIs failure patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

INTERFACE: hIv patieNts TracER For clinicAl assistanCe and rEsearch During COVID 19

NCT05711680

HIV Infections
UNKNOWN

Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients

NCT01019551

HIV-1 Infection
COMPLETED PHASE2

RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection

NCT04064632

HIV Infection
UNKNOWN PHASE4

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

NCT02616029

HIV-1 Infection
COMPLETED PHASE3

Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events

NCT01417949

HIV-Infection
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TPV

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients double PIs failure

Exclusion Criteria

Not Applicable
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Boehringer Ingelheim

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site

Ancona, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Bari, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Benevento, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Bisceglie, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Bologna, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Brescia, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Busto, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Caserta, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Catania, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Cremona, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Florence, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Genova, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Legnano, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Milan, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Napoli, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Padua, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Palermo, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Pavia, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Roma, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Sassari, , Italy

Site Status

Boehringer Ingelheim Investigational Site

Torino, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1182.130

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Italian Registry of HIV-1 Infected Patients With Drug-RESistant Virus to Reverse Transcriptase Inhibitors, InteGrasE and Viral Protease.
NCT04098315 RECRUITING
Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir
NCT06640192 RECRUITING PHASE2
Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- Emtricitabine
NCT01813292 COMPLETED
Establishment of a Database of HIV Subjects Initiating or Simplifying Dual Therapy With Dolutegravir/Lamivudine
NCT06637813 NOT_YET_RECRUITING
Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection
NCT01297127 COMPLETED
Observational, Retrospective, Multicenter Study to Describe the Reasons for the Change of the Regimen of Antiretroviral Therapy in HIV Patients
NCT02039921 COMPLETED
Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection
NCT00062660 APPROVED_FOR_MARKETING
Bitherapy With the Combination of Raltegravir and Darunavir (BIRDi)
NCT03348449 COMPLETED
Immuno-virological Evaluation of Persons Living With HIV (PLWH)
NCT05973825 NOT_YET_RECRUITING NA
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
NCT02121795 COMPLETED PHASE3
Prospective Cohort of HIV/HBV-coinfected Patients in Europe
NCT04984772 ENROLLING_BY_INVITATION
Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen
NCT02191332 COMPLETED
Prospective HIV Chemotherapy Cohort Study
NCT01902693 COMPLETED
Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD
NCT04311944 UNKNOWN NA
Observational Study of Treated and Untreated Acute and Early HIV-1 Infection
NCT00219934 COMPLETED
Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)
NCT02926456 COMPLETED
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
NCT01968551 COMPLETED PHASE3
Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).
NCT04225325 UNKNOWN PHASE4
Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)
NCT00615563 COMPLETED
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
NCT01475838 COMPLETED PHASE3
Duration of Dual Antiretroviral Therapy in Virologically Suppressed People Living With HIV and Factors Associated With Switching to Tritherapy : a Real-life Cohort
NCT06107140 COMPLETED
An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 Infection
NCT01902615 COMPLETED
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
NCT02616783 COMPLETED PHASE3
Efficacy of Raltegravir in a Large Urban HIV Clinical Population in Milan
NCT01467349 COMPLETED
Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens
NCT02191319 COMPLETED